Baird Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $81
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Colleen Kusy has maintained an Outperform rating on Apellis Pharmaceuticals (NASDAQ:APLS) and increased the price target from $71 to $81. This adjustment reflects a positive outlook on the company's stock performance.
January 17, 2024 | 7:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Colleen Kusy reaffirmed an Outperform rating on Apellis Pharmaceuticals and raised the price target to $81, indicating a bullish outlook on the stock.
The increase in price target by Baird suggests a strong conviction in the future performance of Apellis Pharmaceuticals. Such a positive adjustment by a reputable analyst can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100